Cabazitaxel

A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II study

(2011) C. Villanueva et al.   EUROPEAN JOURNAL OF CANCER

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer

(2009) Francisco Robert et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

(2009) A. C. Mita et al.   CLINICAL CANCER RESEARCH

Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial

(2009) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer

(2008) F. Puglisi et al.   ANNALS OF ONCOLOGY

Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa

(2008) D. R. Berthold et al.   ANNALS OF ONCOLOGY

Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy

(2008) V. Dieras et al.   ANNALS OF ONCOLOGY

A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients

(2008) X. Pivot et al.   ANNALS OF ONCOLOGY